Type 2 diabetes mellitus, glycaemic control, associated therapies and risk of rheumatoid arthritis: a retrospective cohort study

Research output: Contribution to journalArticlepeer-review

Standard

Harvard

APA

Vancouver

Author

Bibtex

@article{69fce4c3dc8d4383b82c04ecdb1f9e21,
title = "Type 2 diabetes mellitus, glycaemic control, associated therapies and risk of rheumatoid arthritis: a retrospective cohort study",
abstract = "OBJECTIVE: To compare the incident risk of rheumatoid arthritis (RA) in patients with type 2 diabetes mellitus (T2DM), and to explore the role of glycaemic control and associated therapeutic use on the onset of RA.METHODS: This study was a retrospective cohort study using patients derived from the IQVIA medical research database (IMRD-UK) between 1995 and 2019. 224 551 newly diagnosed patients with T2DM were matched to 449 101 patients without T2DM and followed up to assess their risk of RA. Further analyses investigated the effect of glycaemic control, statin use, and anti-diabetic drugs on the relationship between T2DM and RA using time-dependent Cox regression model.RESULTS: During the study period, the incidence rate for RA was 8.1 and 10.6 per 10 000 person-years in the exposed and unexposed groups respectively. Following adjustment, the hazard ratio (aHR) was 0.73 (95% CI 0.67-0.79). In patients who had not used statins in their lifetime, the aHR was 0.89 (95% CI 0.69-1.14). When quantifying the effects of glycaemic control, anti-diabetic drugs and statins using time-varying analyses, there was no association with glycaemic control (aHR 1.00 (95% CI 0.99-1.00)), use of metformin (aHR 1.00 (95% CI 0.82-1.22)), dipeptidyl peptidase-4 inhibitors (DPP4i) (aHR 0.94 (95% CI 0.71-1.24)), and the development of RA. However, statins demonstrated a protective effect for progression of RA in those with T2DM (aHR 0.76 (95% CI 0.66-0.88), with evidence of duration-response relationship.CONCLUSION: There is a reduced risk of RA in patients with T2DM, that may be attributable to the use of statins.",
keywords = "Type 2 diabetes, rheumatoid arthritis, epidemiology, electronic health records",
author = "Zemedikun, {Dawit T} and Krishna Gokhale and Chandan, {Joht Singh} and Jennifer Copper and Lord, {Janet M} and Andrew Filer and Marie Falahee and Krishnarajah Nirantharakumar and Karim Raza",
note = "Corrected Proof published 16/02/2021. Final Version of Record not yet available as of 08/06/2021.",
year = "2021",
month = jan,
day = "30",
doi = "10.1093/rheumatology/keab148",
language = "English",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",

}

RIS

TY - JOUR

T1 - Type 2 diabetes mellitus, glycaemic control, associated therapies and risk of rheumatoid arthritis

T2 - a retrospective cohort study

AU - Zemedikun, Dawit T

AU - Gokhale, Krishna

AU - Chandan, Joht Singh

AU - Copper, Jennifer

AU - Lord, Janet M

AU - Filer, Andrew

AU - Falahee, Marie

AU - Nirantharakumar, Krishnarajah

AU - Raza, Karim

N1 - Corrected Proof published 16/02/2021. Final Version of Record not yet available as of 08/06/2021.

PY - 2021/1/30

Y1 - 2021/1/30

N2 - OBJECTIVE: To compare the incident risk of rheumatoid arthritis (RA) in patients with type 2 diabetes mellitus (T2DM), and to explore the role of glycaemic control and associated therapeutic use on the onset of RA.METHODS: This study was a retrospective cohort study using patients derived from the IQVIA medical research database (IMRD-UK) between 1995 and 2019. 224 551 newly diagnosed patients with T2DM were matched to 449 101 patients without T2DM and followed up to assess their risk of RA. Further analyses investigated the effect of glycaemic control, statin use, and anti-diabetic drugs on the relationship between T2DM and RA using time-dependent Cox regression model.RESULTS: During the study period, the incidence rate for RA was 8.1 and 10.6 per 10 000 person-years in the exposed and unexposed groups respectively. Following adjustment, the hazard ratio (aHR) was 0.73 (95% CI 0.67-0.79). In patients who had not used statins in their lifetime, the aHR was 0.89 (95% CI 0.69-1.14). When quantifying the effects of glycaemic control, anti-diabetic drugs and statins using time-varying analyses, there was no association with glycaemic control (aHR 1.00 (95% CI 0.99-1.00)), use of metformin (aHR 1.00 (95% CI 0.82-1.22)), dipeptidyl peptidase-4 inhibitors (DPP4i) (aHR 0.94 (95% CI 0.71-1.24)), and the development of RA. However, statins demonstrated a protective effect for progression of RA in those with T2DM (aHR 0.76 (95% CI 0.66-0.88), with evidence of duration-response relationship.CONCLUSION: There is a reduced risk of RA in patients with T2DM, that may be attributable to the use of statins.

AB - OBJECTIVE: To compare the incident risk of rheumatoid arthritis (RA) in patients with type 2 diabetes mellitus (T2DM), and to explore the role of glycaemic control and associated therapeutic use on the onset of RA.METHODS: This study was a retrospective cohort study using patients derived from the IQVIA medical research database (IMRD-UK) between 1995 and 2019. 224 551 newly diagnosed patients with T2DM were matched to 449 101 patients without T2DM and followed up to assess their risk of RA. Further analyses investigated the effect of glycaemic control, statin use, and anti-diabetic drugs on the relationship between T2DM and RA using time-dependent Cox regression model.RESULTS: During the study period, the incidence rate for RA was 8.1 and 10.6 per 10 000 person-years in the exposed and unexposed groups respectively. Following adjustment, the hazard ratio (aHR) was 0.73 (95% CI 0.67-0.79). In patients who had not used statins in their lifetime, the aHR was 0.89 (95% CI 0.69-1.14). When quantifying the effects of glycaemic control, anti-diabetic drugs and statins using time-varying analyses, there was no association with glycaemic control (aHR 1.00 (95% CI 0.99-1.00)), use of metformin (aHR 1.00 (95% CI 0.82-1.22)), dipeptidyl peptidase-4 inhibitors (DPP4i) (aHR 0.94 (95% CI 0.71-1.24)), and the development of RA. However, statins demonstrated a protective effect for progression of RA in those with T2DM (aHR 0.76 (95% CI 0.66-0.88), with evidence of duration-response relationship.CONCLUSION: There is a reduced risk of RA in patients with T2DM, that may be attributable to the use of statins.

KW - Type 2 diabetes

KW - rheumatoid arthritis

KW - epidemiology

KW - electronic health records

U2 - 10.1093/rheumatology/keab148

DO - 10.1093/rheumatology/keab148

M3 - Article

C2 - 33590842

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

ER -